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The evolutionary success of primate lentiviruses reflects their high capacity to mutate and adapt to new host species,
immune responses within individual hosts, and, in recent years, antiviral drugs. APOBEC3G (A3G) and APOBEC3F (A3F)
are host cell DNA-editing enzymes that induce extensive HIV-1 mutation that severely attenuates viral replication. The
HIV-1 virion infectivity factor (Vif), expressed in vivo, counteracts the antiviral activity of A3G and A3F by inducing
their degradation. Other APOBECs may contribute more to viral diversity by inducing less extensive mutations
allowing viral replication to persist. Here we show that in APOBEC3C (A3C)-expressing cells infected with the patient-
derived HIV-1 molecular clones 210WW, 210WM, 210MW, and 210MM, and the lab-adapted molecular clone LAI, viral
G-to-A mutations were detected in the presence of Vif expression. Mutations occurred primarily in the GA context and
were relatively infrequent, thereby allowing for spreading infection. The mutations were absent in cells lacking A3C
but were induced after transient expression of A3C in the infected target cell. Inhibiting endogenous A3C by RNA
interference in Magi cells prevented the viral mutations. Thus, A3C is necessary and sufficient for G-to-A mutations in
some HIV-1 strains. A3C-induced mutations occur at levels that allow replication to persist and may therefore
contribute to viral diversity. Developing drugs that inhibit A3C may be a novel strategy for delaying viral escape from
immune or antiretroviral inhibition.
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Introduction
The evolutionary success of primate lentiviruses is evident
from their prevalence in Old-World primates and their
capacity to spread to new host species, frequently leading to
the emergence of zoonotic disease [1,2]. Establishing persis-
tent infection in individual hosts requires high mutation rates
and rapid and extensive viral adaptation, which allows the
virus to escape from humoral and cell-mediated immune
responses [3,4]. Rapid viral adaptation also produces drug
resistance that limits the effectiveness of therapy in many
patients. Thus, understanding lentiviral genetic variation is
crucial for HIV therapy.
An important mechanism of HIV genetic variation is G-
to-A mutation during reverse transcription [5,6]. Such
mutations can be mediated by a family of DNA-editing
enzymes with a strong preference for speciﬁc dinucleotide
contexts [7–10]. For instance, APOBEC3G (A3G) induces
high frequency of GG-to-AG mutations [11–15] whereas
APOBEC3B (A3B) and APOBEC3F (A3F) cause GA-to-AA
mutations [7,11,12]. In contrast, APOBEC3C (A3C) acts on
both GA and GG dinucleotides, with a preference for GA
over GG [7,12,16]. G-to-A mutations have been detected in
at least 43% of HIV-1-infected patients, indicating that
such mutations occur in a setting of persistent replication
[17].
A3G- and A3F-induced mutations are suppressed by HIV-1
virion infectivity factor (Vif), which is typically expressed in
vivo, thus limiting their contribution to the adaptation of
viral populations [15,18–22]. In contrast, A3B and A3C are
relatively resistant to the effects of Vif [7,16,23], which
suggests they may play a role in HIV diversity. However,
unlike A3C [24], A3B is not expressed in the lymphoid cells
that serve as targets for HIV-1 infection, which limits its
potential role in the evolution of wild-type HIV-1 [9,23].
We hypothesized that G-to-A mutation in vif-expressing
viruses is caused by an APOBEC that does not have a strong
antiviral activity, is relatively resistant to Vif action, and is
expressed in HIV-1 target cells. To contribute to the
adaptation of viral populations, the APOBEC activity should
be weak/moderate, such that mutations are sufﬁciently
infrequent to allow some mutant progeny to survive.
APOBEC3C (A3C) is a candidate because it is expressed in
cells targeted by HIV-1, including PBMC, macrophages, and
thymocytes [24]. A3C can cause mutations in the GA and GG
contexts [7,12]. A3C has diverged by at least 40% from the
A3G, A3F, and A3B, which are known to have antiviral
activity against HIV-1 [7,9,24,25]. Furthermore, a recent
report showed that APOBEC3C exerts potent antiviral
activity against simian immuno-deﬁciency virus, but not to
a lab-adapted clone of HIV-1 [16]. Low-level activity of DNA-
editing enzymes would allow some HIV-1 progeny to be viable
enough to be selected by immune responses or antiviral
drugs.
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mutation and HIV-1 replication using multiple infectious
viruses differing in Gag and/or Pro. The ﬁrst group of
isogenic vif-expressing NL4–3 molecular clones (210WW,
210WM, 210MM, 210MW) contain combinations of pre- (W)
and post-therapy (M) gag and pro genes from an HIV-1-
infected patient who rapidly developed resistance to a
protease inhibitor–containing regimen [26]. A second group
of drug-resistant viruses includes three NL4–3-based molec-
ular clones with point mutations introduced in the protease
and reverse transcriptase (RT) genes. NL4–3 and LAI were
also included as controls.
Results
A3C Expression Is Required for G-to-A Mutation in Magi
and 293T Cells
To determine whether A3C is responsible for inducing G-
to-A mutation in HIV-1, we inhibited A3C expression in HIV-
1-infected Magi cells and examined the viral sequences. Magi
cells, which normally express A3C (Figure 1), were transfected
with siRNA 1 targeting A3C RNA at position 167–185 relative
to the start codon. A FITC-conjugated RNA oligo was
cotransfected to mark the transfected cells. FITC-positive
cells were sorted 48 h after transfection. We found that no
A3C mRNA was detectable in FITC-positive cells transfected
with A3C-speciﬁc siRNA (Figure 2A, lane 3) after 48 h in
culture. By contrast, cells transfected with a control,
scrambled RNA, had normal A3C mRNA levels. The cells
were then infected in a single-round replication assay with
NL4–3 and 210WW viruses produced by 293T transfection
(both virus stocks were p24-normalized, delta env and VSV-G-
pseudotyped). After an additional 24 h in culture, cellular
DNA and RNA were extracted. A3C mRNA was undetectable
by RT-PCR (unpublished data).
The presence of G-to-A mutations in NL4–3 and 210WW
was then examined using a sensitive mutation assay adapted
from Janini et al., 2000 [17] and designed for detecting G-to-A
viral mutants over a more abundant wild-type background.
This assay sensitively detects G-to-A mutants in the viral
population and measures the relative frequency of mutation
in the GA versus GG contexts (see Materials and Methods for
a detailed description).
We found no G-to-A mutation in virus grown in Magi cells
transfected with the A3C siRNA 1 (Figure 2B). By contrast, G-
to-A mutations were detected in a parallel experiment where
Magi cells were transfected with scrambled RNA (Figure 2B),
indicating that A3C can induce G-to-A mutations in 210WW.
The dinucleotide context of G-to-A mutation also correlates
with the activity of A3C since both GA and GG contexts were
modiﬁed with GA relatively more preferred than GG (17 GA
over ﬁve GG, Figure 2B). Surprisingly, no G-to-A mutations
were detected in NL4–3 infections of Magi cells transfected
with the siRNA 1 or with the scrambled RNA (unpublished
data).
To conﬁrm that the siRNA 1 was speciﬁc to A3C, we
examined the expression proﬁle of other APOBEC genes. We
found that the Magi cell line did not express mRNA for A3G
or A3F, either before or after siRNA treatment (Figure 2A,
lanes 5–8). Magi cells do express A3B [27], but A3B mRNA
levels were not altered by the A3C siRNA treatment (Figure
2A, lanes 1 and 2) as expected because there were nine
nucleotide mismatches between the A3C siRNA 1 and A3B
mRNA sequences.
To ensure that the suppression of G-to-A mutations in
siRNA 1–transfected cells is not due to an off-target effect of
the siRNA, we repeated these experiments with a second
siRNA (siRNA 2), which targets residues 107–125, and causes a
partial knockdown of A3C mRNA expression (Figure S3).
When transfected into 293T cells, endogenous A3C mRNA
levels were reduced by 74% and the frequency of G-to-A
mutations was correspondingly reduced by 70% compared to
the control scrambled RNA. siRNA 2 was speciﬁc for A3C
mRNA; no reduction in A3B, A3F, and A3G expression was
observed compared to the scrambled control.
Thus, speciﬁc inhibition of A3C expression by siRNA
eliminated 210WW G-to-A mutations after infection of Magi
(Figure 2B) and 293T cells. This result suggests that A3C
expression is required for the induction of G-to-A mutations
in 210WW.
A3C Expression in SupT1 Cells Is Sufficient for G-to-A
Mutation
To further conﬁrm that A3C in the target cells was
responsible for the G-to-A mutations, the A3C gene was
transfected into SupT1 cells, which do not express A3C
mRNA (Figure 1). A3C cDNA was cloned into an expression
plasmid that expresses the bicistronic A3C-IRES-GFP under
the R PGK promoter and carries the inﬂuenza hemagglutti-
nin (HA) epitope tag (see Materials and Methods). A3C
expression in 293T-transfected cells was conﬁrmed by west-
ern blotting with a polyclonal antibody speciﬁc for HA,
displaying the predicted electrophoretic mobility of 23 kDa
(Figure 3A). The A3C expression plasmid was then trans-
fected into human SupT1 cells and the level of protein
expression was assessed by quantifying GFP by FACS (Figure
3B). After 48 h, the cells were infected with p24 normalized
delta env VSV-G pseudotyped NL4–3 and 210WW viruses
produced by 293T cells. After an additional 24 h, DNA was
extracted, ampliﬁed using the sensitive mutation assay for
detecting G-to-A mutation in the viral population [17], and
sequenced. In SupT1 cells transfected with A3C, G-to-A
mutation was predominately in the GA context with 210WW
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Author Summary
HIV has shown a chameleon-like nature, always changing to adapt
to its environment. Defining the factors that drive and regulate
genetic changes in HIV over time is key to understanding how HIV
causes disease and escapes from the body’s immune responses and
drug treatment. The diversity of HIV has implications for the
development of effective drugs and for fostering better immune
responses. In this study, we showed that a human protein, called
APOBEC3C (A3C), could induce certain mutations in some HIV-1
strains, including those derived from a patient who had developed
rapid drug resistance. Eliminating the expression of this protein
prevented the mutations in two different types of cells. Further-
more, short-term A3C expression was sufficient to cause mutation.
We conclude that A3C is necessary and sufficient to induce
signature mutations in HIV-1. A3C-induced mutations may provide
potential benefit for the virus if the mutation rate is low enough
such that the majority of viruses are able to replicate, while
accumulating a limited number of novel mutations that may allow
the virus to survive in the face of antiviral drugs or immune
responses.showing signiﬁcantly higher levels of mutation in comparison
to NL4–3 (Figure 3C). No mutation was detected following
infection with 210WW or NL4–3 in SupT1 cells transfected
with the empty vector (Figure 3C). Therefore, A3C is
sufﬁcient to induce mutations in the patient-derived infec-
tious molecular clone of HIV-1.
The Replication Kinetics of 210WW Are Not Reduced
Compared to NL4–3 after Spreading Infection in Cells
Expressing A3C
Because 210WW and NL4–3 have different mutation
frequencies in the presence of A3C in a setting of single-
round infection, we wanted to assess the inﬂuence of A3C-
induced mutation on the viral replication kinetics in a
spreading infection. 293T-derived viruses were normalized by
p24 and used to inoculate PBMC, CEMSS, and SupT1 cells,
three cell types that have different APOBEC expression
proﬁles. Consistent with previous reports, we found that
PBMC expressed A3C, A3G, and A3F [9,16], and that SupT1
was negative for all APOBEC RNA analyzed [27] (Figure 1). In
contrast to a previous study [7], we found that CEMSS
expressed A3C only (Figure 1). Viral replication kinetics were
monitored by measuring HIV-1 p24 concentration in the
culture supernatant. We found that 210WW and NL4–3 had
comparable growth kinetics in all three cell types (Figure 4A).
The presence and sequence context of G-to-A mutations in
NL4–3 and 210WW was next examined in the three cell types
at day 5 post infection using the same sensitive mutation
assay as above. Frequent G-to-A mutations were found in
210WW sequences extracted from PBMC and CEMSS cells
(A3C-positive, Figure 4B). Consistent with A3C activity, they
were detected both at GA and GG contexts with GA preferred
to GG [7,12]. In contrast, no G-to-A mutation was detected in
SupT1 cells (Figure 4B); although the viruses had achieved
comparable levels of replication as in the other cells (Figure
4A). NL4–3 sequences showed little to no mutation in any of
the three cell types (Figure 4B). Therefore, A3C does not seem
to reduce the replication kinetics during spreading infection
Figure 2. Inhibition of A3C Expression and G-to-A Mutation by siRNA 1
(A) Magi cells were transfected with siRNA 1 (50 nM) against A3C or with
scrambled RNA. A FITC-conjugated oligo was cotransfected and FITC-
positive cells were sorted 48 h following transfection. PolyAþ RNA was
isolated, and RT-PCR was performed with primers specific for A3B (lanes
1 and 2), A3C (lanes 3 and 4), A3F (lanes 5 and 6), and A3G (lanes 7 and
8). b-Actin (lanes 9 and 10) was used as an internal control. A sample
lacking template DNA (lane 11) was used as a negative control. Lane 12 is
a molecular weight standard.
(B) The transfected cells were infected with the VSV-G-pseudotyped
210WW and collected 24 h later. Viral DNA was amplified using the
sensitive mutation assay and population sequencing was performed to
analyze G-to-A mutation. The G-to-A mutation typically appeared as a
mixture of G and A peaks at a given position, with G, the wild-type
sequence, as the predominant peak. A change from G-to-A was
considered a true mutation only if A represented at least 20% of the
peak.
doi:10.1371/journal.ppat.0030153.g002
Figure 1. Expression of APOBEC mRNAs in Different Cells
Poly AþRNA was isolated from individual cell types and APOBEC reading
frames (A3B, A3C, A3F, and A3G) were amplified with primers specific for
a single ORF. The specificity of the primers was verified by sequencing
the PCR products. RT-PCR reactions for A3B, A3C, A3G, and A3F ORFs
were analyzed by agarose gel electrophoresis. PCR templates were
cDNAs for the indicated cell types or plasmids specific for A3B, A3C, A3G,
or A3F (positive controls). Water was the nontemplate control (NTC), b-
actin was the internal control, and reactions lacking reverse transcriptase
(RT) were also used as control during cDNA preparation (unpublished
data).
doi:10.1371/journal.ppat.0030153.g001
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in A3C susceptibility.
The Frequency of Lethal Mutations Induced by A3C Is Low
in Cells Expressing A3C
To understand why A3C-induced mutations did not reduce
the replication kinetics of 210WW we assessed the number of
stop codons present in a region of RT using a quantitative
assay based on blue and white b-galactosidase complementa-
tion (see Materials and Methods). In this assay, the wild-type
RT sequence gives rise to a blue colony whereas a mutated
sequence containing a stop codon will give rise to a white
colony. At day 5 post infection by 210WW, cellular DNA from
PBMC, CEMSS, and SupT1 were ampliﬁed using primers that
cannot distinguish between mutated and non-mutated
sequences. The PCR fragments, containing six tryptophan
codons susceptible to become stop codons if G-to-A
mutations occur, were inserted in frame with the b-
galactosidase gene. After validating the assay (see Materials
and Methods), we counted the number of white and blue
colonies obtained from the different infections. In SupT1
cells infected with 210WW, four out of 1,219 clones were
white (0.3%). This rate is equivalent to the background of the
assay. Upon sequencing, the few white clones that were found
contained insertion-deletion mutations leading to frame-
shifts, rather than G-to-A mutations leading to stop codons,
consistent with the absence of A3C in SupT1 cells. In
contrast, 78 out of 937 clones from PBMC were white
(8.3%), and 61 out of 1,290 clones from CEMSS were white
(4.7%). The low frequencies of lethal mutations (4%– 8%)
induced in A3C-expressing cells could explain the compara-
ble kinetics observed between 210WW, which is susceptible to
A3C, and NL4–3, which is relatively resistant.
The Overall Rate of G-to-A Mutations in the Viral
Population Is Low in Cells Expressing A3C
The low frequency of lethal mutation suggests that the
overall rate of G-to-A mutation within the viral population
should also be low in cells expressing A3C. In order to
quantify the overall mutation rate, a clonal analysis of a 230-
nt region of pro in proviral DNA of 210WW and NL4–3
infection from PBMC was performed. Neutral primers that
do not distinguish between mutated and non-mutated
sequences were used to amplify 210WW and NL4–3 DNA
from PBMC that had been infected 5 d earlier. PBMC
infection with NL4–3 Dvif virus served as a positive control
for G-to-A mutation. Of 45 210WW clones, 33 were wild type
and 12 were mutated (27%), with only one to two G-to-A
mutations each in the region analyzed. Of 47 NL4–3 clones,
43 were wild type and four were mutated (8%). Of 41 clones
of Dvif virus, four were wild type and 37 were mutated (90%).
We then determined the frequency of mutations leading to
lethal premature stop codons: four of 45 (9%) contained
premature stop codons consistent with the result of the blue
and white b-galactosidase complementation assay and the
non-attenuated replication kinetics of 210WW (Figure 4A).
Two of 47 (4%) NL4–3 clones had lethal stop codons, and 28
of 41 (68%) Dvif clones had lethal stop codons in the pro gene.
G-to-A Mutation May Generate Drug-Resistance Mutations
To investigate whether G-to-A mutation could enhance the
capacity of patient-derived viruses to adapt to antiviral drugs,
we screened mutated clones for drug-resistance mutations.
We looked for pro D30N, a mutation in the protease gene that
occurs during nelﬁnavir treatment [28] and is caused by G-to-
A mutation in the GA context. Such a modiﬁcation was found
in two of 45 (4%) 210WW clones in the absence of drug
selection but in none of the NL4–3 or Dvif clones. These
results suggest that limited G-to-A mutation could be
deleterious for some viral progeny, but surviving progeny
may have greater genetic diversity that could allow adapta-
tion to antiviral drugs.
A3C-Induced G-to-A Mutations Are Not Restricted to
210WW Isolates
To determine if A3C-induced G-to-A mutation occurs in
viruses other than 210WW, and to correlate the susceptibility
Figure 3. Effect of A3C Expression in SupT1
(A) The A3C gene cloned into the pTT-IRES-GFP lentiviral vector with an HA tag was expressed in 293T cells, and the protein detected with a polyclonal
HA antibody.
(B) This construct was used to transfect SupT1 cells. After 48 h, transfection efficiency of the construct was monitored by FACS analysis of GFP
expression.
(C) Transfected SupT1 cells were infected with the VSV-G-pseudotyped 210WW and NL4–3 HIV-1 and collected 24 h later. Viral DNA was amplified using
the sensitive mutation assay, and population sequencing performed to analyze G-to-A mutation. The total number of G-to-A mutations in the protease
region (positions 2255–2485) was counted separately for the GA and GG contexts. No mutations were detected after infection of SupT1 cells transfected
with an empty vector. ND, non-detectable mutations.
doi:10.1371/journal.ppat.0030153.g003
PLoS Pathogens | www.plospathogens.org October 2007 | Volume 3 | Issue 10 | e153 1480
APOBEC3C Induces Limited G-to-A Mutationfor G-to-A mutation to Gag and/or Pro, we examined G-to-A
mutation in a number of viruses. The ﬁrst group is the 210
virus family (210WW, 210MW, 210WM, and 210MM) that
consists of reconstructed HIV-1 molecular clones derived
from combinations of pre- and post-therapy gag and pro genes
from a patient who had developed resistance to ritonavir
within 4 wk of treatment and that were cloned into a NL4–3
genetic background [26]. These molecular clones demonstrate
substantially different phenotypes with respect to drug
susceptibility, replication capacity, and Gag cleavage charac-
teristics [26,29,30]. The difference in replication capacity
between 210WW and 210WM is 5-fold. The chimeric viruses
(MW and WM) have intermediate phenotypes representing a
2.5-fold difference in replication capacity with respect to
210WW [26]. There are 11 amino acid differences between
the wild-type Gag in 210WW and the mutant Gag in 210MM
as well as two amino differences between wild type and
mutant protease (Figure S2). The second group consists of
RT- and protease inhibitor–resistant viruses constructed by
site-directed mutagenesis of NL4–3 (Protease Mutant 1, 2,
and JF4A). NL4–3 and LAI were also used. We repeated the
experiments in Figure 4B using an expanded number of
viruses from 293T transfections and substituting H9 cells for
PBMC (also A3C-, A3G-, and A3F-positive, Figure 1).
Population sequencing followed by the dinucleotide context
analysis of G-to-A mutations was performed on cellular DNA
at day 7 post infection using the G-to-A sensitive detection
assay. Preferential (approximately 15-fold) G-to-A mutation
in the GA as opposed to the GG context was seen in 210WW,
210WM, 210MW, and 210MM (Figure 4C). Susceptibility to G-
to-A mutation was not restricted to the 210 viruses: LAI
showed an intermediate to low level of mutation in H9 and
CEMSS. G-to-A mutations in LAI also occurred predomi-
nantly in the GA context. The 210 viruses showed signiﬁcantly
higher levels of mutation in comparison to the other NL4–3-
based and LAI viruses tested in H9 and CEMSS cells (Figure
4C). No mutations were detected in SupT1 cell infections
with any of the viruses tested.
Target Cell Effect of A3C
To determine whether A3C from the producer cell, target
cell, or both induces G-to-A mutations, we measured
mutations in A3C-positive and A3C-negative target cells
from viruses derived from A3C-positive 293T cells directly, or
after propagation for 7 d in A3C-negative cells (SupT1). Viral
infection titers were normalized by supernatant Gag p24.
Infections were carried out and G-to-A mutations were
determined as described in Figure 4B. We found no G-to-A
Figure 4. G-to-A Mutation of Wild-Type Virus in PBMC and Different Cell Lines
(A) Growth kinetics of 210WW and NL4–3 in PBMC, CEMSS, and SupT1 cells. Cells were infected with p24-normalized viral particles produced from
transfected 293T cells. Virus production was monitored by measuring HIV-1 p24 concentration in the culture supernatant. The data presented are one
from four independent experiments, in which comparable results were obtained.
(B) G-to-A mutation in HIV-1 strains 210WW and NL4–3. DNA was isolated from cell cultures 5 d after infection; the viral protease gene was amplified
using the sensitive mutation assay for detecting G-to-A mutated templates. PCR products were then sequenced as a population. The total number of G-
to-A mutations in the protease region (positions 2255–2485) was counted separately for the GA and GG contexts. ND, non-detected mutations.
(C) Analysis of the GA and GG contexts of the protease gene in the different group of viruses after 7 d of H9 and CEMSS infections. The results presented
are the mean and the standard deviations (error bars) of at least three independent infection experiments.
doi:10.1371/journal.ppat.0030153.g004
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210WW regardless of A3C expression in the producer cells
(Table 1). However, G-to-A mutations were induced in target
cells expressing A3C. The result suggests that only A3C in the
target cell is active.
Discussion
In this study, we asked whether A3C has a role in HIV-1 G-
to-A mutations. We found that transient A3C expression was
sufﬁcient to cause mutation of a patient-derived infectious
HIV-1 molecular clone in SupT1 cells. Reciprocally, speciﬁc
abrogation of A3C expression prevented G-to-A mutation in
Magi and 293T cells, demonstrating that A3C is required for
mutation in these cell lines. Furthermore, G-to-A mutation is
detected in CEMSS cells, which we found express A3C but not
A3B, A3F, or A3G. A role for A3C in PBMC is suggested by the
activity of the enzyme that can act on both GA and GG
contexts: Both mutational patterns are widely observed in
vivo with G-to-A mutation in the GA context more predom-
inant than in the GG context [5,6,17]. The preferential
activity of A3C on GA context reported by previous studies
[7,12,16] is consistent with our ﬁndings. Indeed, in CEMSS
cells that endogenously express only A3C, G-to-A mutation
was predominately detected in the GA context (Figure 4B).
These data are consistent with the notion that A3C is
necessary and sufﬁcient to induce G-to-A mutation in HIV-1.
G-to-A mutations occurring at low rates in a high
background of wild-type viruses were detected in this study
using a sensitive G-to-A detection assay adapted from Janini
et al, 2000 [17]. Although this approach is useful to sensitively
detect G-to-A mutations in the viral population, and to assess
the relative frequency of mutation in the GA versus GG
context, it is not quantitative. To conﬁrm and quantify the
rate of mutation detected in A3C-expressing cells we used the
blue and white complementation assay and clonal analysis of
sequences.
The blue and white complementation assay and clonal
analysis of gene segments ampliﬁed using non-selective
primers indicated that the majority of viral sequences was
not altered after exposure to A3C: 27% of the 210WW clones
harbor only one to two G-to-A mutations. We also found that
mutated sequences containing premature stop codons in-
duced by G-to-A mutation reﬂect less than 9% of the 210WW
clones. A low rate of G-to-A mutation likely explains the
negligible antiviral effect of A3C on the 210 and LAI viruses.
Other studies reported that A3C did not exhibit strong
antiviral activity against HIV-1 NL4–3 replication, which is
consistent with our own observations [7,16]. The minimal
antiviral effect of A3C reﬂects the low frequencies of
mutation documented in blue and white complementation
assay and clonal analysis of virus populations. Limited G-to-A
mutation associated with A3C may be deleterious for some
viral progeny, but surviving progeny would have greater
genetic diversity. Protease D30N mutations, which confer
clinically important resistance to the protease inhibitor
nelﬁnavir [28], appeared in 5% of 210WW clones from PBMC
infections. While other proteins expressed in PBMCs may
have contributed to the D30N mutations observed, A3C is a
likely inducer for the following reasons: A3C is expressed in
PBMCs; D30N mutations were observed exclusively in
infections with 210WW, which is susceptible to A3C, but
not in infections with NL4–3 or NL4–3 Dvif, which are
susceptible to other deaminases; and all three viruses have the
same reverse transcriptase, suggesting that reverse tran-
scriptase errors could not account for the differential rates
of mutation observed in the different infections.
The action of A3C was observed primarily in infectious
molecular clones of HIV-1, derived from a patient who
rapidly developed drug resistance and virological drug failure
during therapy with a protease inhibitor [26]. G-to-A
mutation associated with A3C expression was also observed
in the molecular clone LAI, which may suggest that A3C
action is not restricted to the 210 viruses. Susceptibility to
A3C-mediated mutation was higher in the 210 family of
viruses compared to the NL4–3 family of viruses. The
mechanism for this difference in susceptibility to A3C is
not known, although the 210 family of viruses differs from
NL4–3 in Gag and Pro (the DNA alignment as well as the
amino acid alignment of 210WW, LAI, and NL4–3 is provided
in Figures S1 and S2). The patient-derived gag segment in 210
is 6% divergent from NL4–3 overall. Differences in Gag may
alter the stability of the viral core, or the pre-integration
complex, which would affect how long nascent single-
stranded cDNA is available to bind with A3C in the target
cell. More work is needed to identify the viral determinants of
A3C susceptibility, and to seek clinical correlations of A3C
susceptibility.
The action of A3C differs from that of A3G, A3F, and A3B
in several ways. A3G appears to act both in the virion and the
target cell: target cell action appears to involve impaired
reverse transcription rather than cytidine deamination [31].
A3G, A3F, and A3B cause G-to-A hypermutation when
incorporated in the budding virion, producing lethal hyper-
mutation early in the synthesis of viral cDNA that frequently
occurs in the virion. In contrast, A3C seems to act only in the
target cell based on the following observations: G-to-A
mutation was not observed in SupT1 cells (using the sensitive
and the blue and white assays) that were infected with viruses
produced in 293T cells, which express A3C (Figure 1), while
viruses propagated in SupT1 acquire mutation only when
they infect A3C-expressing cells (Table 1). Target cell action
was further demonstrated by transient expression or tran-
sient knockdown of A3C in target cells, which determined the
appearance of G-to-A mutation in single-cycle infections. The
exposure of the viral cDNA to A3C in the target cell could be
limited, which may decrease the frequency of viral mutation
Table 1. Detection of G-to-A Mutations in 210WW Virus
Produced in either A3C-Positive or AC3-Negative Cells following















G-to-A mutations were detected using the sensitive mutation assay as described in
Materials and Methods. þ indicates mutations,   no mutation.
doi:10.1371/journal.ppat.0030153.t001
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genetic diversity to adapt and escape from immune responses
or antiviral drugs.
HIV diversity is the major obstacle for effective treatment
of HIV patients. It has been suggested that natural genetic
variations in A3G/A3F and/or vif may result in an incomplete
neutralization of those cytidine deaminases allowing the
remaining enzymes to exert a low level of mutation on the
HIV-1 genome and potentially inducing viral diversity
[32,33,34]. Although A3G mutants have been recovered from
different individuals, there is no functional evidence for a
defect in the antiviral activity of those mutants and in their
ability to induce massive hypermutation resulting in defective
viruses [33,34]. Similarly, vif variants that partially fail to
neutralize A3G have been identiﬁed; however, the recovered
proviral sequences were highly hypermutated and replica-
tion-defective [32]. We ﬁnd evidence of a low level of cytosine
deaminase activity in vif-expressing viruses, although some
Vif-A3C interactions have been observed [7,9,16]. A3C
activity may be relatively resistant to Vif [7,19,35,36] because
A3C has a tyrosine instead of the aspartic acid at position
128, which is critical for the interaction with and sensitivity to
Vif. In conclusion, we demonstrate here that A3C is necessary
and sufﬁcient for G-to-A mutations in some HIV-1 strains.
A3C-induced mutations occur at levels that allow replication
to persist and may therefore play a role in driving viral
diversity.
Materials and Methods
Cells and viruses. The cell lines H9, CEMSS, SupT1, Magi, and 293T
were directly obtained from the National Institutes of Health AIDS
Research and Reference Reagent Program. Cell line identity was
conﬁrmed using DNA ﬁngerprinting by PCR ampliﬁcation with
allele-speciﬁc primers (Research Genetics). PBMCs from leukocyte-
enriched fractions of whole blood from HIV-1-seronegative donors
were isolated by density-gradient centrifugation (Histopaque-1077,
Sigma). Cells were stimulated with PHA-P (5 lg/ml, Sigma) for 24 h,
washed, and maintained at 2310
6/ml in RPMI-1640 (Irvine Scientiﬁc)
supplemented with L-glutamine (2 mM), 20% FBS (Gemini Bio-
products), and IL-2 (10 U/ml puriﬁed human, Roche Diagnostics)
before and after infection.
pNL4–3, obtained from the NIH AIDS Research and Reference
Reagent Program (Catalog Number: 114), is a laboratory wild-type
HIV-1 molecular clone. pM46I/L63P/V82T/I84V (Catalog Number:
4595), and pL10R/M46I/L63P/V82T/I84V (Catalog Number: 4596) are
NL4–3-based infectious molecular clones with protease mutations
introduced in vitro. pJF4A (Catalog Number: 1412) is a full-length
infectious molecular clone that is identical to pNL4–3 except for two
nucleotide substitutions introduced by site-directed mutagenesis at
nt 2754 (A-G) and 2755 (C-A) that render it resistant to ddC. pLAI.2
(Catalog Number: 2532) is a laboratory wild-type molecular clone.
The 210 viruses are isogenic infectious molecular clones having the
NL4–3 background and combinations of pre-therapy and post-
therapy gag and pro gene segments from a patient who had developed
resistance mutations to ritonavir 4 wk after treatment [26]. The 210
constructs differ from NL4–3 in a portion of the 59 untranslated
region upstream of gag, gag, and pro (nt 702-2563 relative to NL4–3;
see Figure S1).
210WW has pre-therapy gag and pro, while 210MM has drug-
adapted gag and pro, which contains pro mutations I54V and V82A.
210WM has the pre-therapy gag with drug-adapted pro, and 210MW
has drug-adapted gag with pre-therapy pro.
NL4–3 Denv and 210WW Denv viruses were generated by digesting
each plasmid with Nhe1 restriction enzyme (Invitrogen). The DNA
polymerase I Klenow fragment (New England Biolabs) was used to ﬁll
in the ends and the plasmids were religated using the T4 DNA ligase
(Promega). Pseudotyped VSV-G DEnv NL4–3 and 210WW viruses
were produced by cotransfecting 293T with the pMD.G plasmid
expressing the VSV-G envelope protein [37] and the plasmid
expressing DEnv HIV-1 viruses, respectively.
NL43 Dvif is a NL4–3 variant with three stop codons introduced
into vif by directed mutagenesis (C. de Noronha, unpublished data).
HIV-1 replication and infectivity. Virus stocks were prepared by
Lipofectamine-mediated transfection of 293T cells. The clariﬁed
viral supernatants were quantiﬁed and normalized by HIV-1 Gag p24
ELISA (Perkin Elmer). DNase treatment of viral supernatant was
carried out at 37 8C for 30 min with the equivalent of 10 units DNase
(Sigma)/1 ml of the clariﬁed crude virus. Spreading infections were
monitored over time by accumulation of p24 Gag in the culture
supernatants. Single-cycle infectivity was performed by challenging
the cell lines (5310
5 cells) with VSV-G Denv pseudotyped viruses for
24 h.
APOBEC plasmid construction. PolyAþ RNA was isolated from
cells with the QuickPrep Micro mRNA Puriﬁcation Kit (Pharmacia).
The open reading frames of A3B, A3C, A3F, and A3G were ampliﬁed
by RT-PCR with the following primers: 3B forward 59-ATGAATCCA-
CAGATCAGAAATCC-39 and reverse 59-TCAGTTTCCCT-
GATTCTGG-39; 3C: forward 59-ATGAATCCACAGATCAGAAACC-
39 and reverse 59-TCACTGGAGACTCTCCCGTA-39; 3F: forward 59-
ATGAAGCCTCACTTCAGAAAC-39 and reverse 59-TCACTCGA-
GAATCTCCTGC-39; 3G: forward 59-ATGAAGCCTCACTTCAGAAA-
CACAG-39 and reverse 59-TCAGTTTTCCTGATTCTGGAGAATGG-
39. The amplicons were cloned into pGEM-T easy vectors (Promega)
and conﬁrmed by sequencing. The A3C gene with HA tag sequence at
its 39 terminus was ampliﬁed from mRNA of H9 cells by RT-PCR, and
the identity of the product was conﬁrmed by sequencing. It was then
cloned into pTT-IRES-GFP (a gift from David Fenard, Gladstone
Institute of Virology and Immunology) for protein expression.
Transfection. The 293T or Magi cells were transfected with
Lipofectamine 2000 transfection reagent (Invitrogen), according to
the manufacturer’s recommendations. The SupT1 cells were trans-
fected by Amaxa electroporation technology with the program T29,
according to the manufacturer’s recommendations.
Nucleic acid isolation, RT, PCR, and DNA sequencing. DNA was
extracted from infected cells with the DNA Easy kit (Invitrogen) and
quantiﬁed by spectrometry. PolyA þ RNA was isolated with
QuickPrep Micro mRNA Puriﬁcation kit (Pharmacia). Reverse tran-
scription reaction was performed with random hexamers using
SuperScript III reverse transcriptase (Invitrogen). An RT minus
control was always performed in parallel to check for DNA
contamination. PCR was performed with Easy-A High Fidelity PCR
Cloning Enzyme (Stratagene). APOBEC reading frames (A3B, A3C,
A3F, and A3G) were ampliﬁed with primers speciﬁc for a single gene
and listed above in the APOBEC plasmid construction section. The
speciﬁcity of the primers was veriﬁed by sequencing the PCR
products. The PCR products were sequenced by dye terminator cycle
sequencing with Big Dye v3.1 (Applied Biosystems) or ET Termi-
nators (Amersham Biosciences) on an ABI 3100 microcapillary
sequencer. Raw sequence data was analyzed and aligned using
Sequencher (Gene Codes).
Sensitive mutation assay for the detection of G-to-A mutation. This
assay is designed to detect G-to-A viral mutated sequences present in
a high wild-type background. A nested PCR procedure speciﬁc for a
230-nt region in the protease gene ampliﬁes both G (wt) and A (mut)
species in the GA and GG context using the HIV-1 pro primers Hypa
10 and Hypa 11 in the ﬁrst PCR and DP 16 and DP 17 in the second
round PCR as described [17].
The ﬁrst round PCR uses primers speciﬁc for the mutated
sequences (Hypa 10 and Hypa 11). The goal is to enrich the mutated
sequences that are usually present in low concentration. The second
round PCR uses primers that can amplify both mutated (if present
from the ﬁrst round PCR) and the input wild-type DNA (carried over
from the ﬁrst PCR) [17]. Under these ampliﬁcation conditions, no
PCR-induced mutations were detected using control plasmids as
templates. Protease sequences were determined as population
sequences. A mixture of G and A peaks was typically seen at the
mutation site. A change from G-to-A was considered a true mutation
only if A represented at least 20% of the mixture.
Clonal analysis. The clonal analysis was performed using the
neutral primers DP16–2 and DP17–2. The sequence of DP16–2 is 59-
TATCCTTTAGCTTCCCTCA-39. The sequence of DP17–2 is 59-
TAATGGGAAAATTTAAAGTGCAG-39. PCR products were cloned
in pCR 4-TOPO (Invitrogen). The plasmids were then sequenced and
analyzed for their G-to-A content.
Blue and white beta galactosidase complementation assay. The
genetic assay was carried out with a 111-nucleotide viral DNA
containing a HIV-1 pol fragment that includes six tryptophan codons
susceptible to become stop codons if G-to-A mutations occur. Viral
DNA was ampliﬁed using the primers Nsi-Trp6 Fw: 59-CCA
ATGCATACTCCTAAAT TTAAATTACC CATACAAAA-39 and
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ampliﬁed DNA was phenol extracted, precipitated with ethanol,
subjected to treatment with Nsi1 and SpeI, and then puriﬁed from a
1% agarose gel. This fragment encoding six Trp codons was cloned in
frame into the lacZ fragment of the pGEM-T vector. For this purpose
pGEM-T was digested ﬁrst with Nsi1 and then with SpeI to obtain the
linearized vector, which was puriﬁed from a 1% agarose gel and
treated with alkaline phosphatase before ligation to the PCR
products. Escherichia coli XL-1 Blue was transformed and plated onto
minimal agar plates containing 8% X-Gal (5-bromo-4-chloro-3-
indolyl-d-galactopyranoside) and 20% IPTG (isopropyl-d-thiogalac-
topyranoside). The plates were incubated at 37 8C for approximately
15 h. We validated the assay by ﬁrst mixing 0%–5%–25%–50%–75%–
100% of G-to-A mutated clones with wild-type clones. We then
ampliﬁed each mix, cloned the PCR product, and counted the
number of blue and white colonies. We conﬁrmed that the number of
blue and whites clones obtained after every speciﬁc mixture with the
level of mutated sequences included in the mix. We also determined
that the background of this assay was around 0.3%, which
corresponded to the percentage of white colonies detected using
100% wild-type plasmids. The sequences of the white clones obtained
in this speciﬁc mix revealed insertions or deletions interrupting the
reading frame, and not stop codons. We also sequenced 20 white and
20 blue clones obtained from the other mix to verify their mutation
content and the presence of stop codons. 20/20 blue clones were wild-
type sequences and 20/20 white clones were mutated sequences. Blue
and white clones were counted using the EagleSight (Stratagene)
instrument and conﬁrmed by manual counting.
Western blot analysis. A3C protein expression in 293T transfected
cells was detected by western blot with an HA-probe (Y-11) and HRP
polyclonal antibody speciﬁc for the HA tag (Santa Cruz Biotechnol-
ogy).
RNAi assay. siRNAs targeting A3C from positions 167–185 (siRNA
1) and 107–125 (siRNA 2) bases relative to the start codon were
transcribed in vitro (RiboMax kit, Promega) from an oligo DNA
template containing the T7 promoter synthesized by Invitrogen. The
sequence of the scrambled RNA for both siRNAs was generated with
the Promega siRNA target designer.
For the siRNA transfection, 293T and Magi cells were seeded into
six-well plates at a density of 10
4 cells/ml. After about 2 h, puriﬁed
A3C siRNAs along with RNA oligo conjugated to FITC (Block It kit,
Invitrogen) were transfected into the cells with Lipofectamine 2000,
according to the manufacturer’s protocols. A scrambled siRNA was
transfected separately as a control.
The efﬁciency of transfection was monitored by ﬂuorescent
microscopy at 24, 48, and 72 h after siRNA transfection. For ﬂow
cytometry analysis, the cells were analyzed with a Becton Dickinson
FACS cytometer. Samples were counted and analyzed with FlowJo
software (Tree Star). Non-transfected cells were used as a control.
FITC-positive cells were sorted (DIVA instrument, Becton Dickinson)
for further analysis and infection.
Supporting Information
Figure S1. Nucleic Acid Alignment of 210WW, 210MM, NL4–3, and
LAI Viruses
The alignment includes the segment of the 59 untranslated region
upstream of gag, gag, and pro (nt 702-2563 relative to NL4–3). The dots
indicate the nucleotides that match.
Found at doi:10.1371/journal.ppat.0030153.sg001 (704 KB AI).
Figure S2. Amino Acid Alignment of 210WW, 210MM, NL4–3, and
LAI Viruses
(A) Gag amino acid alignment of 210WW, 210MM, NL4–3, and LAI
viruses. Amino acid position relative to polyprotein start in HXB2: 1–
513. Residue numbers for each line of sequence are provided. The
dots indicate the residues that match.
(B) Protease alignment of 210WW, 210MM, NL4–3, and LAI viruses.
Amino acid position relative to polyprotein start in HXB2: 557–655.
Found at doi:10.1371/journal.ppat.0030153.sg002 (500 KB AI).
Figure S3. Partial Reduction of A3C Expression and G-to-A Mutation
by siRNA 2
(A) 293T cells were transfected with siRNA 2 (50 nM) against A3C or
with scrambled RNA. A FITC-conjugated oligo was cotransfected and
FITC-positive cells were sorted 48 h following transfection. PolyAþ
RNA was isolated, and RT-PCR was performed with primers speciﬁc
for A3B (lanes 1 and 2), A3C (lanes 3 and 4), A3F (lanes 5 and 6), and
A3G (lanes 7 and 8). b-Actin (lanes 9 and 10) was used as an internal
control. A sample lacking template DNA (lane 11) was used as a
negative control. Lane 12 is a molecular weight standard.
(B) The transfected cells were infected with the VSV-G-pseudotyped
210WW and collected 24 h later. Viral DNA was ampliﬁed using the
sensitive mutation assay and population sequencing was performed
to analyze G-to-A mutation. The G-to-A mutation typically appeared
as a mixture of G and A peaks at a given position, with G, the wild-
type sequence, as the predominant peak. A change from G-to-A was
considered a true mutation only if A represented at least 20% of the
peak.
(C) Base composition of 210WW plasmid, 210WW DNA infection of
293Tþscrambled RNA, and 210WW DNA infection of 293TþsiRNA
2 in the region ampliﬁed by the sensitive mutation assay.
Found at doi:10.1371/journal.ppat.0030153.sg003 (786 KB AI).
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The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html) ac-
cession numbers for the genes and proteins mentioned in the text
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